Your browser is no longer supported. Please, upgrade your browser.
SNDX Syndax Pharmaceuticals, Inc. daily Stock Chart
Syndax Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.76 Insider Own0.20% Shs Outstand34.33M Perf Week4.26%
Market Cap603.99M Forward P/E- EPS next Y-1.74 Insider Trans21.18% Shs Float33.16M Perf Month-8.01%
Income-57.00M PEG- EPS next Q-0.46 Inst Own65.20% Short Float6.78% Perf Quarter40.40%
Sales1.50M P/S402.66 EPS this Y36.90% Inst Trans21.67% Short Ratio2.64 Perf Half Y132.97%
Book/sh1.56 P/B10.83 EPS next Y14.50% ROA-68.60% Target Price20.00 Perf Year130.74%
Cash/sh2.83 P/C5.96 EPS next 5Y- ROE-123.60% 52W Range5.35 - 21.97 Perf YTD92.37%
Dividend- P/FCF- EPS past 5Y-3.90% ROI-182.10% 52W High-23.12% Beta1.85
Dividend %- Quick Ratio5.50 Sales past 5Y- Gross Margin- 52W Low215.70% ATR1.83
Employees35 Current Ratio5.50 Sales Q/Q0.00% Oper. Margin- RSI (14)52.06 Volatility6.55% 9.96%
OptionableYes Debt/Eq0.37 EPS Q/Q16.10% Profit Margin- Rel Volume0.74 Prev Close16.78
ShortableYes LT Debt/Eq0.37 EarningsMay 07 AMC Payout- Avg Volume850.64K Price16.89
Recom1.70 SMA20-5.82% SMA5016.09% SMA20070.35% Volume628,221 Change0.66%
May-22-20Upgrade Citigroup Neutral → Buy $26 → $23
May-22-20Downgrade H.C. Wainwright Buy → Neutral $25 → $15
May-18-20Downgrade Citigroup Buy → Neutral
May-11-20Reiterated H.C. Wainwright Buy $19 → $25
Mar-04-20Initiated Barclays Overweight $15
Jan-13-20Reiterated H.C. Wainwright Buy $15 → $17
Mar-08-19Reiterated H.C. Wainwright Buy $22 → $16
Jan-04-19Initiated Robert W. Baird Outperform
Jan-05-18Initiated B. Riley FBR, Inc. Buy $40
Mar-16-17Initiated FBR & Co. Outperform $27
Mar-02-17Initiated Instinet Buy $27
Oct-07-16Initiated Guggenheim Buy
Mar-28-16Initiated Morgan Stanley Overweight $22
Mar-28-16Initiated JMP Securities Mkt Outperform $28
Mar-28-16Initiated Citigroup Buy $24
Jun-02-20 07:55PM  
May-25-20 03:17PM  
May-22-20 04:17PM  
May-21-20 04:35PM  
May-12-20 04:05PM  
May-09-20 10:31PM  
May-07-20 08:10PM  
Apr-30-20 07:51AM  
Apr-29-20 04:35PM  
Apr-28-20 04:09PM  
Apr-27-20 04:05PM  
Apr-14-20 07:00AM  
Apr-03-20 06:04PM  
Mar-05-20 06:54AM  
Mar-03-20 05:55PM  
Feb-18-20 07:00AM  
Feb-07-20 11:05AM  
Feb-04-20 07:01AM  
Jan-31-20 07:00AM  
Jan-30-20 02:11PM  
Jan-24-20 10:20AM  
Jan-10-20 04:05PM  
Dec-17-19 04:39PM  
Dec-10-19 08:08AM  
Dec-09-19 04:05PM  
Nov-17-19 07:14AM  
Nov-11-19 09:30AM  
Nov-07-19 05:55PM  
Nov-06-19 07:00AM  
Oct-31-19 07:00AM  
Oct-28-19 10:32AM  
Oct-23-19 12:44PM  
Sep-17-19 11:42AM  
Sep-11-19 10:04AM  
Aug-29-19 11:41AM  
Aug-28-19 07:00AM  
Aug-12-19 08:46AM  
Aug-09-19 09:37AM  
Aug-07-19 06:25PM  
Aug-05-19 07:00AM  
Jul-31-19 07:00AM  
Jul-30-19 10:38AM  
Jul-12-19 05:41AM  
Jul-10-19 07:00AM  
Jul-04-19 07:26AM  
Jun-13-19 07:00AM  
Jun-08-19 08:28PM  
May-30-19 05:33AM  
May-28-19 11:18AM  
May-16-19 10:45AM  
May-14-19 07:00AM  
May-06-19 06:05PM  
Apr-29-19 07:00AM  
Apr-01-19 10:33AM  
Mar-27-19 07:00AM  
Mar-13-19 03:45AM  
Mar-12-19 01:35PM  
Mar-07-19 04:05PM  
Mar-06-19 07:00AM  
Feb-28-19 07:00AM  
Feb-27-19 04:47PM  
Feb-25-19 10:30AM  
Feb-12-19 07:55AM  
Jan-07-19 07:00AM  
Jan-04-19 12:23PM  
Dec-04-18 12:17AM  
Dec-03-18 10:00AM  
Nov-12-18 08:50AM  
Nov-05-18 06:30PM  
Nov-01-18 04:05PM  
Oct-29-18 07:00AM  
Oct-26-18 08:17AM  
Oct-25-18 04:05PM  
Oct-18-18 08:35AM  
Sep-26-18 07:00AM  
Sep-25-18 04:05PM  
Sep-24-18 04:05PM  
Sep-12-18 03:54PM  
Sep-11-18 12:27PM  
Sep-05-18 05:00PM  
Aug-28-18 07:00AM  
Aug-27-18 08:15AM  
Aug-07-18 06:20PM  
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates are entinostat that is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 in Phase I/II clinical trial inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; and with Tecentriq (atezolizumab) in Phase Ib/II clinical trials to treat patients with HR+ and HER2- metastatic breast cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I/II clinical trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is completed Phase Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; and Merck KGaA and Pfizer. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Morrison BriggsChief Executive OfficerFeb 04Buy8.0012,500100,00043,900Feb 05 04:07 PM